Novel beta-lactone compounds are described. Also described are uses thereof, such as for inhibition of phospholipase A2 activity. Therapeutic uses thereof are also described, such as for the treatment of autoimmune conditions, and/or neural conditions, and/or inflammatory conditions.La présente invention concerne de nouveaux composés bêta-lactone. Linvention concerne également leurs utilisations, notamment pour inhiber lactivité de la phospholipase A2 . Linvention concerne également leurs utilisations thérapeutiques, notamment pour le traitement daffections auto-immunes, et/ou daffections neurales, et/ou daffections inflammatoires.